Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients

International uniform response criteria for multiple myeloma

Brian G.M. Durie, J-L Harousseau, Jesús F. San Miguel et al. · Leukemia · 2006 · 2.6K citations

Hematological Malignancy, Oncology, Malignant Blood Disorder +3

Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome

Hervé Avet‐Loiseau, Michel Attal, Philippe Moreau et al. · Blood · 2007 · 899 citations · Full text

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

Paul G. Richardson, Edie Weller, Sagar Lonial et al. · Blood · 2010 · 855 citations · Full text

Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial

Pieter Sonneveld, Ingo Schmidt‐Wolf, Bronno van der Holt et al. · Journal of Clinical Oncology · 2012 · 819 citations · Full text

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

Nicholas Mitsiades, Constantine S. Mitsiades, Vassiliki Poulaki et al. · Blood · 2002 · 666 citations · Full text